Lanreotide
What the Research Actually Shows
Human: 1 studies, 3 groups · Animal: 0 · In Vitro: 0
The self-injectable somatostatin analog that rewrote the treatment rules for silent neuroendocrine tumors — and why CLARINET changed everything
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Lanreotide is an FDA-approved peptide drug that treats hormone-producing tumors and a growth hormone disorder called acromegaly. It works like octreotide — mimicking a natural hormone called somatostatin that tells your body to stop releasing too many hormones — but comes in a prefilled syringe you can inject yourself at home. In 2014, a landmark study called CLARINET proved something no trial had shown before: lanreotide could slow the growth of tumors that produce no symptoms at all. Patients on lanreotide went more than two years without their tumors growing, compared to 18 months on placebo. That trial turned lanreotide from a symptom-management drug into a cancer-fighting one — and it did it in the hardest-to-justify population: people whose tumors weren't causing any problems yet.
Lanreotide is a synthetic cyclic octapeptide — eight amino acids arranged in a disulfide-bridged ring — designed to mimic the natural hormone somatostatin. It belongs to the same drug class as octreotide, binding primarily to somatostatin receptor subtype 2 (SSTR2), but its formulation is fundamentally different: the Autogel delivery system creates a supersaturated aqueous solution that forms a gel depot at the injection site, providing true 28-day sustained release from a single deep subcutaneous injection.
That formulation difference matters more than it sounds. Octreotide LAR requires a healthcare provider to administer an intramuscular injection using a specialized reconstitution kit. Lanreotide Autogel comes in a prefilled syringe designed for self-injection — a distinction that has meaningful implications for patient autonomy, healthcare resource use, and treatment adherence in patients who may need monthly injections for years.
But the real significance of lanreotide in oncology isn't the syringe — it's the CLARINET trial. Published in 2014, CLARINET enrolled 204 patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors — tumors that produce no hormonal symptoms and therefore had no prior clinical indication for somatostatin analog therapy. The trial demonstrated a hazard ratio of 0.47 for progression-free survival (PMID 25099546), proving that lanreotide slowed tumor growth in cancers where there was no symptom-control rationale for treatment. This was the paradigm shift: somatostatin analogs are antiproliferative agents, not just symptom managers.
Lanreotide is the second chapter in the Cancer and Oncology cluster's somatostatin story. Where octreotide's PROMID trial first hinted at antiproliferative effects in midgut NETs, CLARINET proved it decisively — and in the tougher population. The third chapter, Lutathera, would take the same SSTR2-binding principle and weaponize it with radiation.
In This Article
Quick Facts: Lanreotide at a Glance
Type
Synthetic cyclic octapeptide somatostatin analog (8 amino acids)
Also Known As
Somatuline Depot, Somatuline Autogel, BIM 23014, lanreotide acetate
Generic Name
Lanreotide acetate
Brand Name
Somatuline Depot (US), Somatuline Autogel (EU/international)
Related Compounds
Octreotide (same class, PROMID trial, Chapter 1), Lutathera (radiolabeled SSTR agonist, Chapter 3), pasireotide (multi-receptor somatostatin analog)
WADA Status
Not on WADA Prohibited Lists
Molecular Weight
~1,096 Da
Peptide Sequence
D-2Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂ with Cys2-Cys7 disulfide bridge
Endogenous Origin
Synthetic analog of somatostatin-14 (SST-14), a 14-amino-acid neuropeptide produced in the hypothalamus, GI tract, and pancreas
Primary Molecular Function
Somatostatin receptor agonist (SSTR2 > SSTR5 > SSTR3) — inhibits hormone secretion and cell proliferation in receptor-positive tumors
Active Fragment
Retains the somatostatin pharmacophore motif in a stabilized cyclic framework with unique D-2Nal substitution for enhanced metabolic stability
Half-Life
Terminal half-life ~23–30 days (Autogel depot); effective duration 28 days per injection
Clinical Programs
GEP-NETs (CLARINET Phase III), acromegaly, carcinoid syndrome, thymic NETs, bronchial NETs. Decades of clinical use
Route
Deep subcutaneous injection (Autogel prefilled syringe, self-injectable, monthly)
FDA Status
Approved (2007): acromegaly. (2014): GEP-NETs based on CLARINET. Standard of care for nonfunctioning NETs
Community Interest
Not a community-use compound. Prescription-only pharmaceutical used exclusively in clinical settings
Evidence Tier
1 Approved Drug
Verdict
Strong Foundation
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Lanreotide?
Pronunciation: lan-REE-oh-tide
Most cancers announce themselves — pain, weight loss, bleeding, a lump you can feel. Neuroendocrine tumors often don't. Many of them sit quietly in the pancreas or small intestine, growing slowly, producing no hormonal symptoms, giving no sign that anything is wrong. For years, the medical profession had no reason to treat these silent tumors with somatostatin analogs. After all, somatostatin analogs were symptom-control drugs — and these tumors weren't causing symptoms.
Lanreotide changed that logic. It is a synthetic octapeptide somatostatin analog — eight amino acids in a disulfide-bridged ring — that binds primarily to somatostatin receptor subtype 2 (SSTR2), the same receptor that octreotide targets. Structurally, lanreotide differs from octreotide in several amino acid positions, most notably a D-2-naphthylalanine substitution and a valine where octreotide has a threonine. These differences give lanreotide a slightly broader receptor affinity profile, including meaningful SSTR3 binding that octreotide largely lacks.
But the real innovation is the delivery system. Lanreotide Autogel is a supersaturated aqueous solution that spontaneously forms a gel depot when injected deep subcutaneously. This gel slowly releases lanreotide over 28 days — no reconstitution, no PLGA microspheres, no healthcare provider required. A patient (or caregiver) can self-inject from a prefilled syringe once a month, a practical advantage that matters enormously when treatment may continue for years.
PLAIN ENGLISH
Lanreotide is a lab-made version of a natural "slow down" hormone. It comes in a prefilled syringe that you can inject yourself once a month. The key discovery was that it doesn't just control symptoms from hormone-producing tumors — it actually slows the growth of tumors that aren't producing any symptoms at all.
Origins and Discovery
Lanreotide was developed at Beaufour-Ipsen (now Ipsen) in France during the late 1980s as part of the same wave of somatostatin analog development that produced octreotide at Sandoz. Both compounds emerged from the same insight: somatostatin-14's therapeutic potential was locked behind a 2–3 minute half-life that made clinical use impossible.
Where Sandoz created octreotide by building a minimal cyclic octapeptide around the Phe-Trp-Lys-Thr pharmacophore, Ipsen's team took a parallel approach. Lanreotide (BIM 23014) incorporated the same core binding motif but with distinct amino acid substitutions — D-2-naphthylalanine in place of D-phenylalanine, and valine in place of threonine — creating a compound with a different receptor selectivity profile and different physicochemical properties.
Those physicochemical properties turned out to be critical. Lanreotide forms nanotube assemblies in aqueous solution at high concentrations — a property that enabled the Autogel formulation. The supersaturated solution spontaneously gels at the injection site, creating a sustained-release depot without the need for biodegradable polymer microspheres. This was not just a formulation convenience; it was the innovation that made self-injection possible.
Somatuline Depot/Autogel received FDA approval in 2007 for acromegaly. The oncology indication — treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs — followed in 2014 based on the CLARINET trial results.
Mechanism of Action
Somatostatin Receptor Binding and Selectivity
Lanreotide binds to three of the five somatostatin receptor subtypes, with highest affinity for SSTR2, followed by SSTR5 and SSTR3. All five SSTRs are G-protein coupled receptors that inhibit adenylyl cyclase, but their tissue distribution and downstream signaling profiles differ.
SSTR2 is the primary therapeutic target in neuroendocrine oncology. It is overexpressed on the surface of most well-differentiated neuroendocrine tumors — the same receptor that makes tumors visible on OctreoScan and DOTATATE PET/CT imaging. When lanreotide binds SSTR2, it triggers a cascade of antiproliferative signals: inhibition of the PI3K/Akt pathway, activation of protein tyrosine phosphatases (particularly SHP-1), and cell cycle arrest at G1 (PMID 26658512).
The SSTR3 affinity is where lanreotide may differ from octreotide in clinically relevant ways. SSTR3 activation has been associated with apoptosis induction in some tumor models — a mechanism that doesn't just slow growth but actively kills cells. Whether this translates to clinical superiority remains unproven in head-to-head trials, but it provides a mechanistic rationale for investigating lanreotide in tumor types where SSTR3 expression is prominent.
PLAIN ENGLISH
Lanreotide docks onto a specific receptor (SSTR2) that sits on the surface of most neuroendocrine tumor cells. When it binds, it sends a "stop dividing" signal inside the cell. It may also trigger a "self-destruct" signal through a second receptor (SSTR3) — something its cousin octreotide doesn't do as strongly.
Antisecretory Effects
Beyond antiproliferative activity, lanreotide suppresses the release of growth hormone, insulin, glucagon, gastrin, VIP, and other peptide hormones — the same broad antisecretory activity that makes somatostatin analogs effective for acromegaly and functional NET symptom control.
Autogel Depot Pharmacology
The Autogel formulation achieves therapeutic plasma concentrations within 24 hours of injection and maintains them for 28 days. Peak levels typically occur within the first few days, followed by a sustained plateau. This pharmacokinetic profile enables true once-monthly dosing with consistent receptor occupancy — a meaningful advantage for antiproliferative efficacy, where continuous receptor suppression matters.
PLAIN ENGLISH
The gel that forms at the injection site acts like a slow-release capsule under your skin, steadily releasing lanreotide for a full month from a single shot.
Key Research Areas and Studies
The CLARINET Trial — Paradigm Shift in NET Treatment
The CLARINET trial (Caplin et al., 2014, PMID 25099546) is the most consequential study in lanreotide's clinical history and arguably one of the most important trials in the Cancer and Oncology cluster. It was a prospective, randomized, double-blind, placebo-controlled Phase III trial enrolling 204 patients with nonfunctioning, well- or moderately-differentiated GEP-NETs.
The study design was deliberately provocative. Previous somatostatin analog trials in NETs — including PROMID with octreotide — had enrolled patients with functional tumors that produced hormonal symptoms. CLARINET enrolled patients whose tumors produced no symptoms at all. The question it asked was radical: should you treat a cancer that isn't currently bothering the patient?
Results: - Progression-free survival hazard ratio: 0.47 (95% CI 0.30–0.73, p<0.001) - Median PFS: not reached in the lanreotide group vs. 18.0 months for placebo - PFS at 24 months: 65.1% (lanreotide) vs. 33.0% (placebo) - Disease stabilization rate: 62% (lanreotide) vs. 22% (placebo) - Objective response rate: minimal in both arms — this was a stabilization story, not a shrinkage story
PLAIN ENGLISH
CLARINET asked a gutsy question: if a tumor isn't causing any problems, should you still treat it? The answer was yes. Patients on lanreotide had a 53% lower risk of their tumors growing compared to placebo. Most tumors didn't shrink — they stopped growing. That's the definition of disease control.
Acromegaly Efficacy
Lanreotide has been a first-line medical therapy for acromegaly since 2007. Meta-analyses demonstrate normalization of GH (<2.5 ng/mL) and IGF-1 in approximately 50–60% of treatment-naive patients — comparable to octreotide LAR (PMID 29562532). The self-injectable formulation provides a practical advantage in this chronic disease where treatment continues indefinitely.
Carcinoid Symptom Control
For functional NETs producing carcinoid syndrome (diarrhea, flushing, bronchoconstriction), lanreotide is effective and well-tolerated. Patient preference studies consistently favor the self-injectable Autogel over provider-administered octreotide LAR for convenience and autonomy.
The CLARINET Story — Why Nonfunctioning Tumors Mattered
Before CLARINET, the clinical logic for treating NETs with somatostatin analogs ran like this: the tumor produces excess hormones → the hormones cause symptoms → block the hormones with an SSA → symptoms improve. Nonfunctioning NETs didn't fit this logic. They had the receptors, but no hormonal symptoms to treat.
The oncology community had hints from PROMID (octreotide in midgut NETs, PMID 19858101) that somatostatin analogs might have a direct antiproliferative effect — PROMID's hazard ratio of 0.34 was striking. But PROMID enrolled both functional and nonfunctional tumors, making it impossible to disentangle symptom control from tumor growth inhibition.
CLARINET solved this by deliberately excluding functional tumors. The entire patient population had nonfunctioning NETs — no diarrhea, no flushing, no hormonal symptoms to confuse the picture. When lanreotide showed a 53% reduction in progression risk in this population, it proved something the field had suspected but couldn't confirm: somatostatin analogs are genuinely antiproliferative, independent of their antisecretory effects.
This distinction matters beyond NETs. It established a principle — peptides that bind surface receptors on tumor cells can inhibit tumor growth through direct intracellular signaling, not just hormonal suppression. Lutathera would take that same receptor-binding principle and add a radioactive warhead.
PLAIN ENGLISH
Doctors used to give these drugs to stop hormone-related symptoms. CLARINET showed the drugs also slow tumor growth directly — even when there are no symptoms to treat. That's a fundamentally different kind of medicine.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Lanreotide slows tumor growth in neuroendocrine tumors"” | CLARINET Phase III (N=204): PFS HR 0.47 (p<0.001) in nonfunctioning GEP-NETs. Definitive evidence. PMID 25099546 | Supported |
| “"Lanreotide controls acromegaly"” | FDA-approved indication since 2007. Normalizes GH/IGF-1 in ~50–60% of treatment-naive patients. | Supported |
| “"Lanreotide controls carcinoid symptoms"” | Effective for diarrhea and flushing in functional NETs. Well-established clinical use. | Supported |
| “"Lanreotide is equivalent to octreotide"” | No large head-to-head RCT. Meta-analyses suggest comparable efficacy for acromegaly and symptom control. CLARINET and PROMID used different populations, making direct comparison impossible. | Mixed Evidence |
| “"Self-injection is as effective as provider-administered injection"” | Bioequivalence data supports comparable drug levels. Patient preference studies favor self-injection. | Supported |
| “"Lanreotide can shrink tumors"” | CLARINET showed minimal objective response rates. Lanreotide stabilizes tumors; it rarely shrinks them. | Mixed Evidence |
| “"Lanreotide works in all neuroendocrine tumors"” | CLARINET enrolled GEP-NETs (pancreas and midgut). Data in bronchial, thymic, and other primary sites is limited. | Mixed Evidence |
| “"Lanreotide has fewer side effects than octreotide"” | Both have similar GI and gallbladder side effect profiles. No definitive RCT comparing safety. Self-injection reduces injection-site burden. | Mixed Evidence |
| “"Lanreotide prevents neuroendocrine tumors"” | No study has tested lanreotide as a preventive agent. Antiproliferative effect applies to existing tumors only. | Unsupported |
| “"Lanreotide cures cancer"” | No somatostatin analog cures cancer. Lanreotide slows progression and controls symptoms. Disease control, not cure. | Unsupported |
| “"Lanreotide is useful for non-NET cancers"” | Very limited and preliminary data in hepatocellular carcinoma and other solid tumors. Not established. | Unsupported |
| “"SSTR3 binding gives lanreotide an advantage over octreotide"” | Mechanistically plausible — SSTR3 activation may induce apoptosis. No clinical data demonstrating superiority attributable to this mechanism. | Theoretical |
The Human Evidence Landscape
CLARINET (Caplin et al., 2014, PMID 25099546)
Design: Double-blind, placebo-controlled, Phase III RCT Population: 204 patients with nonfunctioning, well- or moderately-differentiated GEP-NETs (Grade 1–2), Ki-67 <10% Intervention: Lanreotide autogel 120 mg deep SC every 28 days vs. placebo Key finding: PFS HR 0.47 (95% CI 0.30–0.73, p<0.001). Median PFS not reached (lanreotide) vs. 18.0 months (placebo). PFS at 24 months: 65.1% vs. 33.0%. Limitations: Included only well/moderately-differentiated tumors. Excluded high-grade (Grade 3) NETs. No overall survival benefit demonstrated (crossover may have confounded OS analysis). Enrolled predominantly stable-disease patients — open question whether results apply to rapidly progressing tumors.
Acromegaly Pivotal Trials
Design: Multiple Phase III trials leading to 2007 FDA approval Population: Treatment-naive and pre-treated acromegaly patients Key finding: GH normalization (<2.5 ng/mL) and IGF-1 normalization in approximately 50–60% of treatment-naive patients. Non-inferior to octreotide LAR in meta-analytic comparisons (PMID 29562532). Limitations: No single large head-to-head RCT against octreotide LAR. Meta-analyses depend on cross-trial comparison.
Carcinoid Syndrome Studies
Design: Open-label studies and clinical experience Key finding: Effective control of diarrhea and flushing in functional NETs. Patient preference data favors self-injectable lanreotide over provider-administered octreotide LAR. Limitations: Most evidence is open-label. Controlled data for symptom endpoints is less robust than CLARINET's antiproliferative data.
Safety, Risks, and Limitations
Established Safety Profile (15+ Years Post-Approval)
Lanreotide's safety profile reflects its class identity — the side effects are somatostatin analog side effects, shared with octreotide:
Gastrointestinal effects (most common): Diarrhea (37–65%), abdominal pain (19–34%), nausea. These are typically mild to moderate and often improve with continued treatment.
Gallbladder (class effect): Cholelithiasis (gallstones) in 14–26% of patients. This is a direct consequence of somatostatin-mediated inhibition of gallbladder contractility and bile flow. Baseline and periodic ultrasound monitoring is recommended. Symptomatic gallstones may require cholecystectomy.
CRITICAL DISCLAIMER
Gallstone formation is not a rare side effect — it occurs in roughly one in five patients on long-term somatostatin analog therapy. Most gallstones are asymptomatic, but patients should be aware of the risk and undergo monitoring.
Injection site reactions: Induration, pain, and nodule formation at the deep SC injection site. These are specific to the Autogel formulation and generally mild.
Glucose metabolism: Hyperglycemia or hypoglycemia — somatostatin suppresses both insulin and glucagon, and the net effect on glucose homeostasis varies by patient. Diabetic patients require glucose monitoring adjustments.
Cardiac: Sinus bradycardia in 3–7% of patients, usually asymptomatic. Caution in patients on beta-blockers or with pre-existing conduction abnormalities.
Hypothyroidism: Rare suppression of TSH. Thyroid function monitoring recommended during long-term use.
Safety Advantage: Self-Injection
The Autogel self-injection system eliminates the need for monthly healthcare provider visits for injection — reducing injection-associated anxiety, healthcare resource use, and the risk of injection-related complications from IM administration (hematoma, sciatic nerve injury with gluteal IM injection).
PLAIN ENGLISH
Lanreotide has the same basic side effects as octreotide — stomach issues and gallstones are the most common. The main safety advantage is the self-injectable syringe, which means fewer trips to a medical office and lower risk of injection complications.
Legal and Regulatory Status
FDA-Approved
Somatuline Depot is FDA-approved for two indications: - Acromegaly (2007): Long-term treatment in patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy - GEP-NETs (2014): Treatment of adults with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival
EMA and International
Somatuline Autogel is approved across the EU, UK, Japan, and most major markets for similar indications.
Generic/Biosimilar Status
As a synthetic peptide, lanreotide is potentially amenable to generic manufacture. Ipsen's market exclusivity has driven biosimilar interest, though the complex Autogel formulation presents manufacturing challenges.
Compounding
Not applicable. Lanreotide is a prescription pharmaceutical manufactured by Ipsen. Not available from compounding pharmacies or peptide vendors.
Research Protocols and Formulation Considerations
Autogel Formulation
Lanreotide Autogel is a supersaturated aqueous solution that spontaneously forms gel-like nanotubes upon injection. This unique self-assembling property enables sustained drug release without polymer microspheres — distinguishing it from octreotide LAR's PLGA-based depot system.
Storage and Handling
Autogel prefilled syringes are stored refrigerated (2–8°C). They should be brought to room temperature before injection. No reconstitution or mixing is required — the device is ready to inject.
Administration
Deep subcutaneous injection in the upper outer quadrant of the buttock. Can be administered by the patient, a caregiver, or a healthcare provider after proper training.
Dosing in Published Research
The following table summarizes dosing protocols for Lanreotide as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.
FDA-Approved Clinical Dosing
GEP-NETs (CLARINET protocol):
| Parameter | Value |
|---|---|
| Dose | 120 mg |
| Route | Deep subcutaneous injection |
| Frequency | Every 28 days |
| Duration | Continued until disease progression or unacceptable toxicity |
| Dose adjustment | Not applicable — CLARINET used a single fixed dose |
| Parameter | Value |
|---|---|
| Starting dose | 90 mg deep SC every 28 days |
| Titration range | 60–120 mg every 28 days |
| Titration basis | GH and IGF-1 normalization |
| Target | GH <2.5 ng/mL and normal age/sex-adjusted IGF-1 |
PLAIN ENGLISH
Lanreotide dosing is straightforward: one injection under the skin once a month. For tumors, the dose is always 120 mg. For acromegaly, your doctor adjusts the dose based on hormone levels.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Lanreotide combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Lanreotide with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
| Compound | Type | Evidence Tier | Verdict | Primary Mechanism | Target/Receptor | Landmark Trial | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|---|
| Octreotide | Cyclic octapeptide SSA (8 aa, disulfide) | Tier 1 — Approved Drug | Strong Foundation | SSTR2/5 agonist → antisecretory + antiproliferative | SSTR2, SSTR5 | PROMID (N=85, TTP HR 0.34) | Phase III RCT; 30+ years clinical use | Approved 1988 (acromegaly, carcinoid, GEP-NETs) | Not prohibited | Gallstones (15–30%); glucose metabolism effects |
| Lanreotide | Cyclic octapeptide SSA (8 aa, disulfide) | Tier 1 — Approved Drug | Strong Foundation | SSTR2/3/5 agonist → antiproliferative in nonfunctioning NETs | SSTR2, SSTR3, SSTR5 | CLARINET (N=204, PFS HR 0.47) | Phase III RCT; 15+ years post-approval | Approved 2007 (acromegaly); 2014 (GEP-NETs) | Not prohibited | Same class as octreotide; gallstones; glucose effects |
| Lutathera | Radiolabeled peptide (¹⁷⁷Lu-DOTATATE) | Tier 1 — Approved Drug | Strong Foundation | SSTR2-targeted PRRT → intracellular beta-radiation → DNA damage | SSTR2 | NETTER-1 (N=229, PFS HR 0.21) | Phase III RCT + 504-pt registry | Approved January 2018 (SSTR+ GEP-NETs) | Not prohibited | Myelosuppression; MDS/AML risk (~2%); requires nuclear medicine facility |
| Motixafortide | Cyclic peptide (14 aa) | Tier 2 — Clinical Trials | Reasonable Bet | CXCR4 antagonist → stem cell mobilization + tumor immune sensitization | CXCR4 | GENESIS (N=122, 92.5% vs. 26.2% mobilization) | Phase III + Phase 2a (N=199 total) | Not approved (Phase 3 complete) | Not prohibited | No FDA approval yet; competes with approved plerixafor |
| Melflufen | Peptide-drug conjugate (dipeptide-melphalan) | Tier 2 — Clinical Trials | Thin Ice | Aminopeptidase-activated intracellular melphalan release → DNA crosslinking | Aminopeptidase N (CD13) | OCEAN (N=495, PFS HR 0.79 but OS HR 1.104) | Phase III RCT (N=652 total) | Approved Feb 2021; WITHDRAWN Feb 2024 | Not prohibited | Worse OS than comparator; severe myelosuppression; market withdrawal |
| Cilengitide | Cyclic RGD pentapeptide (5 aa) | Tier 2 — Clinical Trials | Thin Ice | αvβ3/αvβ5 integrin antagonist → antiangiogenic | αvβ3, αvβ5 integrins | CENTRIC (N=545, OS HR 1.02) | Phase III RCT (N=891 total) | Not approved; development discontinued | Not prohibited | Definitive Phase III failure (HR 1.02); development abandoned |
style="color:#0F4C5C;font-size:28px;font-weight:700;margin:48px 0 16px 0;line-height:1.2">Frequently Asked Questions
What is lanreotide and what is it used for?
How is lanreotide different from octreotide?
What did the CLARINET trial prove?
Does lanreotide shrink tumors?
Can I inject lanreotide myself?
What are the most common side effects?
How long do I need to take lanreotide?
Is lanreotide available as a generic?
Does lanreotide work for all types of cancer?
What is the relationship between lanreotide and Lutathera?
Can lanreotide be used alongside chemotherapy?
How is lanreotide monitored during treatment?
Summary of Key Findings
Lanreotide is an FDA-approved somatostatin analog with one of the strongest evidence bases in peptide oncology. The CLARINET trial — a double-blind, placebo-controlled Phase III study in 204 patients — demonstrated that lanreotide significantly prolongs progression-free survival in nonfunctioning GEP-NETs (HR 0.47, p<0.001), establishing somatostatin analogs as antiproliferative agents in tumors with no hormonal symptoms to treat.
The compound's safety profile is well-characterized over 15+ years of clinical use. GI side effects and gallstone formation are the primary concerns, shared across the somatostatin analog class. The Autogel self-injectable formulation provides a meaningful practical advantage over octreotide LAR for patients on long-term therapy.
Lanreotide occupies a pivotal position in the Cancer and Oncology cluster's somatostatin narrative: where octreotide's PROMID trial first demonstrated antiproliferative potential, CLARINET confirmed it — in the harder population, with the more rigorous study design.
PLAIN ENGLISH
Lanreotide is a proven cancer drug that slows the growth of certain slow-growing tumors called neuroendocrine tumors. The evidence is strong — it comes from a major clinical trial, not just lab studies. It's safe enough that patients inject it themselves at home once a month.
Verdict Recapitulation
Lanreotide's place in the evidence hierarchy is unambiguous. FDA-approved across two indications, supported by a landmark Phase III RCT, and backed by 15+ years of clinical experience in hundreds of thousands of patients — this is a compound where the research has already shown what it can do. The remaining questions are about optimization and extension: which tumor subtypes benefit most, whether SSTR3 binding provides a real advantage over octreotide, and how lanreotide integrates with newer agents like Lutathera in treatment sequencing.
For readers considering Lanreotide, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Lanreotide
Further Reading and Resources
If you want to go deeper on Lanreotide, the evidence landscape for cancer & oncology peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Cancer & Oncology Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Lanreotide — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Caplin ME, Pavel M, Ćwikła JB, et al. (2014). "Lanreotide in metastatic enteropancreatic neuroendocrine tumors." New England Journal of Medicine, 371(3), 224–233. PMID 25099546
- Cives M, Kunz PL, Morse B, et al. (2015). "Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors." Endocrine-Related Cancer, 22(1), 1–9. PMID 26658512
- Melmed S, Bronstein MD, Chanson P, et al. (2018). "A consensus statement on acromegaly therapeutic outcomes." Nature Reviews Endocrinology, 14(9), 552–561. PMID 29562532
- Rinke A, Müller HH, Schade-Brittinger C, et al. (2009). "Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group." Journal of Clinical Oncology, 27(28), 4656–4663. PMID 19858101
- Ipsen. (2014). Somatuline Depot (lanreotide) Prescribing Information. US FDA
- Öberg K, Knigge U, Kwekkeboom D, et al. (2012). "Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up." Annals of Oncology, 23(Suppl 7), vii124–vii130. PMID 22997445
DISCLAIMER
Lanreotide is an FDA-approved prescription medication. The information presented in this article is for educational purposes only. Off-label uses discussed here may not be supported by the same level of evidence as the approved indications. Always follow the guidance of your prescribing physician.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 11, 2026. Next scheduled review: October 08, 2026.